COVID-19 Topic Center

Featured Stories

News
Labeling Error Prompts Class I Recall
March 05, 2021
A Class I recall has been issued for 34,860 single-dose vials of cisatracurium besylate injection from Meitheal Pharmaceuticals Inc.
Video
Alliance Writes Open Letter Aimed at Helping Speciality Pharmacy Improve Patient Care
March 03, 2021
Gary Kerr, PharmD, MBA, chief pharmacy officer, Baystate Health, and president of HOSP, discusses a recent open letter that the Health System Owned…
Commentary
Talking Therapeutics: How to Talk to Patients About the COVID-19 Vaccines
March 03, 2021
In the first installment, Dr Jennings breaks down the COVID-19 vaccines, and explains how to discuss them with patients.
Commentary
Legal Briefs: Pharmacist Pleads Guilty to Federal Charges, Federal Court Issues Restraining Order Against Pharmacy, and More
March 01, 2021
Ann Latner, JD, breaks down three legal cases including, a pharmacist who plead guilty to federal charges for sabotaging COVID-19 vaccines and an…
News
Antibiotic Recalled Over Impurity Findings
February 26, 2021
Ascend Laboratories is recalling nine lots of cephalexin for oral suspension because impurity results during testing were “at [the] higher side of…
News
Countless Homebound Patients Still Wait for COVID-19 Vaccine Despite Priority of Older Adults
February 25, 2021
Health organizations have begun sending doctors and nurses to apartment buildings and private homes to vaccinate homebound older adults, but the…
Interview
Improving Vaccine Delivery, Operations
February 24, 2021
Adnan Iqbal, CEO and co-founder, Luma Health, identifies what is lacking in vaccine delivery and operations, and offers tips for health…
Commentary
Identifying, Improving Safety Gaps in Sterile Pharmacy Compounding Systems and Practices: Part I
February 24, 2021
Damon Birkemeier, PharmD, FDA/ISMP safe medication management fellow, discusses survey results concerning compounding technologies and common safety…
Commentary
Predicting the Need for SGLT2 Inhibitors for Future Heart Failure
February 23, 2021
“The SGLT2i are an expensive group of drugs in comparison to other goal-directed medical therapies for HfrEF, says Mark Munger, PharmD. “Perhaps this…
Back to Top